Metrics as of 10/17/2026, 10:05 AM (Berlin time), refresh in progress.
Ovid Therapeutics Stock
Ovid Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Margaret Alexander
- Employees
- 23
- Market cap
- $420 M
- IPO
- 05/05/2017
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A…
Ovid Therapeutics stock: price history
1D
-4.9%
1W
-12.6%
1M
-19.8%
6M
-26.1%
YTD
+31.9%
1Y
+36.9%
2Y
+82.2%
5Y
-40.3%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~4% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Ovid Therapeutics
Analyst assessment of Ovid Therapeutics
PRICE TARGET LOW
US$5.00
CONSENSUS
US$6.25
MEDIAN
US$6.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
11
BUY
3
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 11/09/2026
Ovid Therapeutics stock metrics
P/E
-4.48
P/B
0.76
EV/EBITDA
-11.82
RETURN ON EQUITY
-7.2%
NET MARGIN
-2,047.6%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.7%
FLOAT SHARES
163,388,140
AVG. DAILY VOLUME (30D)
1,637,544
Insider transactions (SEC)
Carter Charles Ross
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Ovid Therapeutics stock
What does Ovid Therapeutics do?
Ovid Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Margaret Alexander, the company employs around 23 people.
The IPO was on 05/05/2017; the stock trades on NASDAQ under the ticker OVID.
What do analysts say about Ovid Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 11/09/2026).
The average price target is US$6.25, ranging from US$5.00 to US$8.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Ovid Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Ovid Therapeutics pay a dividend?
No, Ovid Therapeutics currently does not pay a dividend.
Which stocks are comparable to Ovid Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Ovid Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Ovid Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.